Vax바카라사이트 쇼미더벳bio secures domestic patent for high-purity, high-cytotoxicity NK 바카라사이트 쇼미더벳 proliferation core technology

[by Yu, Suin] Vax바카라사이트 쇼미더벳bio announced on July 1 that it has completed patent registration in Korea for its core proprietary technology, ‘Composition for Proliferation of Natural Killer 바카라사이트 쇼미더벳s Including Feeder 바카라사이트 쇼미더벳s.’

This patent represents an advanced technology that enables the mass production of high-purity, high-cytotoxicity natural killer (NK) 바카라사이트 쇼미더벳s using ‘Feeder 바카라사이트 쇼미더벳s’ independently developed by Vax바카라사이트 쇼미더벳bio.

Vax바카라사이트 쇼미더벳bio completed patent registration for this technology in Japan in April and is currently pursuing registration in the United States, Europe, China, Canada, Australia, and Hong Kong. Given that Japan is known for applying particularly stringent evaluation standards to foreign biotechnology patents, the company stated that securing registration in both Korea and Japan serves as strong validation of the technology’s originality and technical completeness.

This technology is distinguished by its superior amplification rate and 바카라사이트 쇼미더벳 purity compared to conventional feeder 바카라사이트 쇼미더벳-based methods, significantly increasing the production efficiency of NK 바카라사이트 쇼미더벳 therapies. Leveraging this technology, Vax바카라사이트 쇼미더벳bio successfully completed a Phase 2a clinical trial for ‘VCB-1102 (development code),’ an NK 바카라사이트 쇼미더벳 therapy candidate targeting hepato바카라사이트 쇼미더벳ular carcinoma.

“As evidenced by the successful patent registrations in both Korea and Japan, the originality and competitiveness of our NK 바카라사이트 쇼미더벳 therapy production technology have been recognized on the global stage,” said Lee Je-jung, CEO of Vax바카라사이트 쇼미더벳bio. “Building on this foundation, we aim not only to reinforce the commercialization potential of NK 바카라사이트 쇼미더벳 therapies but also to broaden the scope of our 바카라사이트 쇼미더벳 therapy platform to include next-generation pipelines such as bone marrow infiltrating lymphocytes and dual-target chimeric antigen receptors (CARs), thereby further strengthening our competitiveness in the global market.”

Conversely, Vax바카라사이트 쇼미더벳bio has recently expanded its intellectual property (IP) portfolio by securing a series of patents related to its CAR pipeline. These include patents for a ‘monobody-based chimeric antigen receptor’ and a ‘novel method for manufacturing natural killer 바카라사이트 쇼미더벳s, as well as a liver cancer treatment method using the same.’

Moreover, the recent selection of CAR-MIL (chimeric antigen receptor myeloinfiltrating lymphocyte) therapy for multiple myeloma and dual-targeting chimeric antigen receptor T 바카라사이트 쇼미더벳 (CAR-T) therapy for solid tumors as national projects has drawn significant attention to the company’s capabilities in developing and commercializing next-generation therapeutic pipelines.